Pharmaceutical Product, Method of Production and Method of Application of the Pharmaceutical Product
The claimed pharmaceutical product is obtained by interaction between a selenium-containing compound with alpha, alpha-dichlorocarboxylic acid, stabilized by nutric acid with the amount of nitric acid not exceeding 5 pts. wt., preferably 1-3 pts. As a selenium-containing compound the solution of the selenious acid in the amount of no more than 20 pts. wt., preferably 0.5-10.0 pts. wt. is used during the interaction. The product can also contain additional 5-20% of dimethylsulfoxide. The production process of the pharmaceutical product is carried out by interaction between a selenium-containing compound with alpha, alpha-dichlorocarboxylic acid, stabilized by nutric acid with the amount of nitric acid not exceeding 5 pts. wt., preferably 1-3 pts., and as a selenium-containing compound the solution of the selenious acid in the amount of no more than 20 pts. wt., preferably 0.5-10.0 pts. wt. is used during the interaction, which is carried out at the temperature not exceeding 70° C., preferably at 20-30° C. The pharmaceutical product used for the treatment of benign, viral, pre-malignant and malignant non-metastatic skin lesions, dysplastic lesions of visible mucous coats and other skin lesions, should be applied to the lesion focus on days 1, 2-3, 7-9 and 22-24 of a treatment.
1 . Pharmaceutical product obtained by interaction between selenium-containing compound and alpha, alpha-dichlorocarboxylic acid is distinguished by the fact that the selenious acid solution (with the amount of selenious acid no more than 20 pts. wt.) and alpha, alpha-dichloropropionic acid, stabilized by nitric acid (with the amount of nitric acid no more than 5 pts. wt.) are used in the interaction as selenium-containing compound.
2 . Pharmaceutical product as in claim 1 , is distinguished by the alpha, alpha-dichlorocarboxylic acid being the 2,2-dichloropropionic acid.
3 . Pharmaceutical product as in claim 1 , is distinguished by the amount of nitric acid being 1-3 pts. wt.
4 . Pharmaceutical product as in claim 1 , is distinguished by the amount of selenious acid being 0.5-10 pts. wt.
5 . Pharmaceutical product as in claim 1 or 2 , is distinguished by the fact that it contains additional 5-20% of dimethylsulfoxide.
6 . Method of production of the pharmaceutical product as in claim 1 by interaction between selenium-containing compound and alpha, alpha-dichlorocarboxylic acid with temperature no higher than 70° C., is distinguished by the fact that the selenious acid solution (with the amount of selenious acid of 0.5-20 pts. wt.) and alpha, alpha-dichloropropionic acid, stabilized by nitric acid (with the amount of nitric acid no more than 5 pts. wt.) are used in the interaction as selenium-containing compound.
7 . Method as in claim 4 , is distinguished by the fact that the interaction is carried out at 20-30° C.
8 . Method as in claim 4 or 5 , is distinguished by the amount of nitric acid which is 1-3 pts. wt.
9 . Method of application of the pharmaceutical product as in claim 1 for treatment of benign, viral, pre-malignant and malignant non-metastatic skin lesions, dysplastic lesions of visible mucous coats and other skin lesions, is distinguished by the fact that it is applied to the lesion focus on days 1, 2-3, 7-9 and 22-23 of treatment.